Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer

NCT02306096 · tracked via the Priya Life Science Sweden tracker

Sponsor

Lund University

Phase

Observational

Started

2010-08

Last updated

2026-08-27

Condition(s) studied

Breast Neoplasms

Study summary

This study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing. Gene expression profiles, mutational profiles, and transcript isoform-level data will be analyzed in the context of patient information, clinicopathological variables, and outcome, with the purpose to develop new molecular diagnostic assays for breast cancer. Additional genome-scale RNA, DNA, and protein analyses will be performed in the future.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * suspicion or confirmed diagnosis of primary breast cancer * signed informed consent Exclusion Criteria: * lack of signed informed consent

Primary outcome measure(s)

Biomarkers and clinicopathological information — up to 20-years
Analysis of genomic data (biomarkers) and their relationship to patient and tumor clinicopathological information; assessment of analytical validity.
Invasive disease-free survival — up to 20-years
Different biomarkers will be analysed in the context of invasive disease-free survival (IDFS) at different time-points for different subgroups of the prospective cohort, for example for all patients receiving a particular therapy or patients with tumors of a specific molecular subtype.

Trial sites (10)

Facility	City	Region	Status
Södra Älvsborg Hospital	Borås	Sweden	Recruiting
Hallands Hospital Halmstad	Halmstad	Sweden	Suspended
Helsingborg Hospital	Helsingborg	Sweden	Recruiting
Kirurgiska kliniken	Jönköping	Sweden	Suspended
Blekinge County Hospital	Karlskrona	Sweden	Recruiting
Central Hospital Kristianstad	Kristianstad	Sweden	Recruiting
Skåne University Hospital	Lund	Sweden	Recruiting
Skåne University Hospital	Malmö	Sweden	Recruiting
Uppsala University Hospital	Uppsala	Sweden	Recruiting
Central Hospital Växjö	Vaxjo	Sweden	Recruiting

More Lund University trials in Sweden

Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders Recruiting

Effects of Delayed Cord Clamping During Resuscitation of Newborn Near Term and Term Infants Active, not recruiting

Effect of Probiotic Supplements on Osteoarthritis Outcomes Active, not recruiting

Light in Healthcare Environment (Ljus i sjukhusmiljö) Recruiting

Prospective RELOC-AGE: How Do Housing Choices and Relocation Matter for Active Ageing? Active, not recruiting

Other trials for the same condition

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) Recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) Active, not recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02306096 on ClinicalTrials.gov ↗ ← All trials in Sweden